SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 3,134 Shares of Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,134 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $16.71, for a total transaction of $52,369.14. Following the sale, the senior vice president owned 277,375 shares in the company, valued at $4,634,936.25. This represents a 1.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Stock Up 0.6%

Shares of NASDAQ:SIBN opened at $17.79 on Tuesday. The firm has a 50 day simple moving average of $14.79 and a 200 day simple moving average of $15.49. SiBone has a 52 week low of $11.48 and a 52 week high of $21.89. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.34 and a current ratio of 9.99. The company has a market cap of $788.99 million, a PE ratio of -45.47 and a beta of 0.67.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.07. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. The firm had revenue of $52.59 million for the quarter, compared to analysts’ expectations of $51.16 million. As a group, research analysts expect that SiBone will post -0.44 earnings per share for the current year.

Hedge Funds Weigh In On SiBone

A number of hedge funds have recently modified their holdings of the stock. Royal Bank of Canada raised its holdings in shares of SiBone by 98.5% during the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after acquiring an additional 736 shares in the last quarter. Versant Capital Management Inc grew its stake in SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after purchasing an additional 887 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in SiBone by 0.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 225,001 shares of the company’s stock valued at $4,437,000 after purchasing an additional 997 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in SiBone by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after purchasing an additional 1,053 shares in the last quarter. Finally, Larson Financial Group LLC increased its position in SiBone by 42.3% in the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock worth $70,000 after purchasing an additional 1,061 shares during the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SIBN has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of SiBone in a research report on Thursday. Wall Street Zen lowered SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Truist Financial reaffirmed a “buy” rating and set a $18.00 target price (down from $20.00) on shares of SiBone in a research note on Tuesday, May 12th. Finally, TD Cowen dropped their target price on SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $23.00.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.